FluoGuide A/S (SE:FLUO)
:FLUO
Top Page
FluoGuide A/S
(FLUO)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr38.00
▲(5.56% Upside)
Action:ReiteratedDate:04/11/26
The score is primarily held down by weak financial performance (minimal revenue, sustained losses, and heavy cash burn alongside higher 2025 debt). Technical indicators provide some offset with an improving trend versus key moving averages and positive MACD, but valuation remains constrained by negative earnings and the lack of a dividend yield.
Positive Factors
Equity capital buffer
A materially larger equity base provides a durable capital buffer to absorb development losses and extend runway without immediate insolvency risk. This strengthens the company’s ability to fund clinical programs or seek strategic partnerships over the next 2–6 months while avoiding immediate cash-collapse scenarios.
Negative Factors
Persistent heavy cash burn
Large, sustained negative operating cash flows force continued external financing, increasing dilution and creating ongoing funding risk. Over the medium term this constrains investments in pivotal trials or commercialization, and makes the company dependent on capital markets or partners to avoid cutting programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Equity capital buffer
A materially larger equity base provides a durable capital buffer to absorb development losses and extend runway without immediate insolvency risk. This strengthens the company’s ability to fund clinical programs or seek strategic partnerships over the next 2–6 months while avoiding immediate cash-collapse scenarios.
Read all positive factors
FluoGuide A/S (FLUO) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr632.72M
Dividend YieldN/A
Average Volume (3M)8.21K
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue GrowthN/A
EPS Growth4.46%
CountrySE
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-1.28
Shares Outstanding16,349,314
10 Day Avg. Volume11,579
30 Day Avg. Volume8,206
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)6.10
Price to Sales (P/S)0.00
P/FCF Ratio-8.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.08
Revenue Forecast (FY)N/A
FluoGuide A/S Business Overview & Revenue Model
Company Description
FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for...
How the Company Makes Money
FluoGuide’s expected revenue model is based on commercializing its fluorescent imaging agent(s) for use alongside existing fluorescence-capable surgical imaging equipment, primarily through (1) product sales of its imaging agent (e.g., per-dose/pe...
FluoGuide A/S Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 385.00K | 423.00K | 6.51M | 9.61M |
| Gross Profit | -571.17K | 385.00K | 423.00K | 6.51M | 9.61M |
| EBITDA | -40.42M | -32.81M | -43.90M | -32.21M | -28.65M |
| Net Income | -40.39M | -28.96M | -38.38M | -27.34M | -23.77M |
Balance Sheet | |||||
| Total Assets | 88.34M | 28.38M | 29.61M | 35.62M | 53.31M |
| Cash, Cash Equivalents and Short-Term Investments | 78.84M | 18.61M | 21.67M | 26.01M | 46.76M |
| Total Debt | 28.30M | 624.00K | 10.83M | 205.00K | 57.00K |
| Total Liabilities | 33.78M | 5.31M | 16.89M | 3.65M | 14.61M |
| Stockholders Equity | 54.56M | 23.07M | 12.72M | 31.97M | 38.70M |
Cash Flow | |||||
| Free Cash Flow | -37.83M | -30.00M | -31.81M | -37.71M | -15.06M |
| Operating Cash Flow | -37.83M | -29.15M | -31.81M | -37.65M | -15.06M |
| Investing Cash Flow | -30.61M | -987.00K | -37.00K | -117.00K | 0.00 |
| Financing Cash Flow | 99.33M | 27.08M | 27.50M | 17.02M | 51.18M |
FluoGuide A/S Technical Analysis
Positive
36.00
Price Trends
35.03
Positive
35.84
Positive
38.48
Positive
Market Momentum
0.71
Positive
56.00
Neutral
30.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLUO, the sentiment is Positive. The current price of 36 is below the 20-day moving average (MA) of 36.72, above the 50-day MA of 35.03, and below the 200-day MA of 38.48, indicating a bullish trend. The MACD of 0.71 indicates Positive momentum. The RSI at 56.00 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:FLUO.
FluoGuide A/S Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr641.88M | -60.92 | -48.65% | ― | -60.33% | 58.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr632.72M | -6.71 | ― | ― | ― | 4.46% | |
44 Neutral | kr376.80M | -6.44 | -79.60% | ― | ― | 31.62% | |
43 Neutral | kr132.50M | -1.72 | -199.86% | ― | 69.03% | 23.10% | |
42 Neutral | kr409.65M | -0.91 | -108.15% | ― | 270.64% | 62.29% | |
42 Neutral | kr24.20M | -0.24 | -186.13% | ― | ― | 0.30% |
* Healthcare Sector Average
SE:FLUO
FluoGuide A/S
38.70
-2.20
-5.38%
SE:QLINEA
Q-linea AB
22.00
-22.63
-50.71%
SE:ACE
Ascelia Pharma AB
2.97
0.23
8.39%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
1.56
-5.08
-76.50%
SE:GUARD
Guard Therapeutics International AB
1.20
-11.05
-90.20%
SE:NANEXA
Nanexa AB
3.90
2.60
200.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.